(Q44785944)

English

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

scientific article published on 27 November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 December 2017

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity (English)

1 reference

Europe PubMed Central

6 December 2017

1 reference

based on heuristic

inferred from title

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

object named as

Eftyhia Vardas

3

0 references

Giuseppe Pantaleo

22

object named as

Giuseppe Pantaleo

1 reference

Europe PubMed Central

6 December 2017

2

object named as

Walter Jaoko

1 reference

Europe PubMed Central

6 December 2017

Andrew James McMichael

20

object named as

Andrew J McMichael

1 reference

Europe PubMed Central

6 December 2017

Linda Sylvia Klavinskis

11

object named as

Linda Klavinskis

1 reference

Europe PubMed Central

6 December 2017

author name string

Barry S Peters

1

1 reference

Europe PubMed Central

6 December 2017

George Panayotakopoulos

4

1 reference

Europe PubMed Central

6 December 2017

Patricia Fast

5

1 reference

Europe PubMed Central

6 December 2017

Claudia Schmidt

6

1 reference

Europe PubMed Central

6 December 2017

Jill Gilmour

7

1 reference

Europe PubMed Central

6 December 2017

Mampedi Bogoshi

8

1 reference

Europe PubMed Central

6 December 2017

Gloria Omosa-Manyonyi

9

1 reference

Europe PubMed Central

6 December 2017

Len Dally

10

1 reference

Europe PubMed Central

6 December 2017

Bashir Farah

12

1 reference

Europe PubMed Central

6 December 2017

Tony Tarragona

13

1 reference

Europe PubMed Central

6 December 2017

Pierre-Alexandre Bart

14

1 reference

Europe PubMed Central

6 December 2017

Andrew Robinson

15

1 reference

Europe PubMed Central

6 December 2017

Colleen Pieterse

16

1 reference

Europe PubMed Central

6 December 2017

Wendy Stevens

17

1 reference

Europe PubMed Central

6 December 2017

Richard Thomas

18

1 reference

Europe PubMed Central

6 December 2017

Burc Barin

19

1 reference

Europe PubMed Central

6 December 2017

James A McIntyre

21

1 reference

Europe PubMed Central

6 December 2017

Tomás Hanke

23

1 reference

Europe PubMed Central

6 December 2017

Job Bwayo

24

1 reference

Europe PubMed Central

6 December 2017

language of work or name

0 references

publication date

27 November 2006

1 reference

Europe PubMed Central

6 December 2017

1 reference

Europe PubMed Central

6 December 2017

25

1 reference

Europe PubMed Central

6 December 2017

11

1 reference

Europe PubMed Central

6 December 2017

2120-2127

1 reference

Europe PubMed Central

6 December 2017

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

HIV vaccine fails in phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Safety profile of recombinant canarypox HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

AIDS vaccine models: challenging challenge viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

HIV vaccines: new frontiers in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.11.016

1 reference

Europe PubMed Central

6 December 2017

1 reference

Europe PubMed Central

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44785944&oldid=2041138228"